了解多发性骨髓瘤或 CD19+ 淋巴细胞增殖性疾病 (LPD) CAR-T 治疗后克隆和非克隆血细胞减少的机制
了解 CAR-T 疗法后克隆和非克隆血细胞减少的机制
This clinical trial evaluates the impact of preexisting and therapy-emergent germline and somatic variants on cytopenia in patients with multiple myeloma or CD19 positive lymphoproliferative disorder (LPD) following chimeric antigen receptor T-cell (CAR-T) therapy. The most common adverse event after CAR-T therapy is lower than normal blood cells (cytopenia) and up to one third of patients experience cytopenia that last longer than 30 days post-infusion. Germline and somatic variants are changes in genes found using cancer genomic tests. Cancer genetic/genomic testing is a series of tests that find specific changes in cancer cells or in blood deoxyribonucleic acid. Identifying gene mutations may help identify the risk of cytopenia in patients with multiple myeloma or CD19 positive LPD following CAR-T therapy.
研究概览
地位
详细说明
PRIMARY OBJECTIVE:
I. Determine the preexisting and therapy-emergent germline and somatic variants associated with an increased risk of clonal and non-clonal cytopenia following CAR-T cell therapy on research basis.
SECONDARY OBJECTIVE:
I. Characterize the baseline transcriptomic signature associated with non-clonal and clonal cytopenia following CAR-T therapy on research basis.
OUTLINE:
Patients undergo bone marrow aspiration and hair, saliva, buccal swab, or skin sample collection up to 14 days prior to lymphodepleting (LD) therapy. Patients undergo clinical follow-up (CFU) on day 90 post-CAR-T therapy. Patients with unexplained cytopenia also undergo bone marrow aspiration for sequencing analysis on day 90 and at development of myeloid neoplasm post-cytotoxic therapies (MN-pCT) during CFU. Patients also undergo bone marrow aspiration at determination of clonal evolution or myeloid neoplasm if not done during CFU on day 90.
Patients with unexplained cytopenia at day 90 are followed up every 90 days for up to 2 years until resolution. Patients without unexplained cytopenia are followed clinically for up to 2 years.
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Clinical Trials Referral Office
- 电话号码:855-776-0015
- 邮箱:mayocliniccancerstudies@mayo.edu
学习地点
-
-
Arizona
-
Scottsdale、Arizona、美国、85259
- 招聘中
- Mayo Clinic in Arizona
-
接触:
- Clinical Trials Referral Office
- 电话号码:855-776-0015
- 邮箱:mayocliniccancerstudies@mayo.edu
-
首席研究员:
- Cecilia Y. Arana Yi, MD
-
-
Florida
-
Jacksonville、Florida、美国、32224-9980
- 招聘中
- Mayo Clinic in Florida
-
接触:
- Clinical Trials Referral Office
- 电话号码:855-776-0015
- 邮箱:mayocliniccancerstudies@mayo.edu
-
首席研究员:
- Talha Badar, MD
-
-
Minnesota
-
Albert Lea、Minnesota、美国、56007
- 招聘中
- Mayo Clinic Health System in Albert Lea
-
接触:
- Clinical Trials Referral Office
- 电话号码:855-776-0015
- 邮箱:mayocliniccancerstudies@mayo.edu
-
首席研究员:
- Mina S. Hanna, MD
-
Mankato、Minnesota、美国、56001
- 招聘中
- Mayo Clinic Health System-Mankato
-
接触:
- Clinical Trials Referral Office
- 电话号码:855-776-0015
- 邮箱:mayocliniccancerstudies@mayo.edu
-
首席研究员:
- Amrit B. Singh, MBBS
-
Rochester、Minnesota、美国、55905
- 招聘中
- Mayo Clinic in Rochester
-
接触:
- Clinical Trials Referral Office
- 电话号码:855-776-0015
- 邮箱:mayocliniccancerstudies@mayo.edu
-
首席研究员:
- Mithun V. Shah, MD, PhD
-
-
Wisconsin
-
Eau Claire、Wisconsin、美国、54701
- 招聘中
- Mayo Clinic Health System-Eau Claire Clinic
-
接触:
- Clinical Trials Referral Office
- 电话号码:855-776-0015
- 邮箱:mayocliniccancerstudies@mayo.edu
-
首席研究员:
- Eyad S. Al-Hattab, MD
-
La Crosse、Wisconsin、美国、54601
- 招聘中
- Mayo Clinic Health System-Franciscan Healthcare
-
接触:
- Clinical Trials Referral Office
- 电话号码:855-776-0015
- 邮箱:mayocliniccancerstudies@mayo.edu
-
首席研究员:
- Scott H. Okuno, MD
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Age ≥ 18 years
- Histologically or cytologically confirmed diagnosis of multiple myeloma (MM) as defined in International Myeloma Working Group (IMWG) criteria or a CD19+ lymphoproliferative disorder (LPD) as defined by 2016 World Health Organization (WHO) classification
- Provide written informed consent
- Willingness to provide mandatory bone marrow aspirate specimens for correlative research. All bone marrow aspirate samples are collected during a clinical procedure
- Willingness to provide mandatory hair follicle or skin punch biopsy specimens (skin punch biopsy specimens will be obtained from Mayo Clinic Rochester patients only) for correlative research
- Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)
- Willingness to provide mandatory saliva or buccal swab sample for correlative research
Exclusion Criteria:
- Ineligible for CAR-T therapy
- Patients diagnosed with myeloid neoplasm before CAR-T therapy
学习计划
研究是如何设计的?
设计细节
- 主要用途:支持治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Supportive care (bone marrow aspiration, CFU)
Patients undergo bone marrow aspiration and hair, saliva, buccal swab, or skin sample collection up to 14 days prior to LD therapy. Patients undergo CFU on day 90 post-CAR-T therapy. Patients with unexplained cytopenia also undergo bone marrow aspiration for sequencing analysis on day 90 and at development of MN-pCT during CFU. Patients also undergo bone marrow aspiration at determination of clonal evolution or myeloid neoplasm if not done during CFU on day 90. |
Undergo bone marrow aspiration Ancillary studies Undergo hair, buccal, and saliva sample collection
其他名称:
Undergo CFU
其他名称:
Receive genetic counselor consultation Undergo sequencing analysis
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Pathogenic and likely pathogenic germline and somatic variants associated with increased risk
大体时间:At baseline
|
The count and percentage of patients with the presence of somatic or germline variants will be reported. The number, type, and function of somatic variants will also be reported. |
At baseline
|
|
Unexplained cytopenia
大体时间:At day 90
|
Unexplained cytopenia will be defined per World Health Organization (WHO)-5 as a combination of any of the following: hemoglobin < 12 g/dL in females, hemoglobin < 13 g/dL in males, absolute neutrophil count < 1.8 x 10^9/L and platelets < 150 x 10^9/L. Logistic regression will be used to identify the presence or absence of baseline germline and somatic mutations associated with unexplained cytopenia. An odds ratio and 95% confidence interval will be reported. |
At day 90
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Development of myeloid neoplasm post-cytotoxic therapies (MN-pCT)
大体时间:Up to 2 years
|
Assessed as development of MN-pCT at any time following CAR-T infusion. MN-pCT is defined per The World Health Organization- Five Well-Being Index (WHO-5). The count and percentage of patients with the presence of somatic or germline variants will be reported. The number, type, and function of somatic variants will also be reported. |
Up to 2 years
|
合作者和调查者
赞助
调查人员
- 首席研究员:Mithun V. Shah, MD、Mayo Clinic in Rochester
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
- 血管疾病
- 心血管疾病
- 肿瘤
- 免疫系统疾病
- 组织学类型的肿瘤
- 血液病
- 淋巴系统疾病
- 免疫增生性疾病
- 肿瘤,浆细胞
- 止血障碍
- 副蛋白血症
- 血液蛋白失调
- 出血性疾病
- 半身和淋巴疾病
- 多发性骨髓瘤
- 淋巴增生性疾病
- 医疗保健质量,访问和评估
- 调查技术
- 流行病学方法
- 临床实验室技术
- 诊断技术和程序
- 诊断
- 医疗保健评估机制
- 医疗保健质量
- 公共卫生
- 环境与公共卫生
- 卫生服务
- 医疗机构的劳动力和服务
- 预防保健服务
- 免疫学技术
- 遗传技术
- 遗传服务
- 诊断服务
- 流行病学研究
- 流行病学研究特征
- 染色质免疫沉淀
- 高通量核苷酸测序
- 序列分析
- 序列分析,DNA
- 免疫沉淀
- 队列研究
- 标本处理
- 基因检测
- 染色质免疫沉淀测序
- 后续研究
- 遗传咨询
其他研究编号
- MC230818
- 24-005734 (其他标识符:Mayo Clinic Institutional Review Board)
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.